[Use of a synchronized protocol of cytostatic drugs in the treatment of advanced lung cancer].
A synchronised programme consisting of VCR, CTX and MTX has been employed in 57 patients suffering fom lung carcinoma. Average survival was 10.6 months and overall tolerance was good. The best indications are intermittent long-term treatment and retreatment of patients with cancer recalcitrant to the same drugs. With the simplification of cell kinetics study techniques, more meaningful results can be expected in the application of this treatment programme.
D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D003520:Cyclophosphamide; D008727:Methotrexate
Osservazioni sull'impiego di un protocollo sincronizzato di citostatici nella terapia del cancro polmonare avanzato.